Rifamycin sodium primary indications include the treatment of tuberculosis, leprosy, and other bacterial infections resistant to more common antibiotics. In recent years, research has also explored its potential in treating conditions including traveler’s diarrhea and certain non-tuberculous mycobacterial infections. Its therapeutic use is listed as antibiotics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Rifamycin SV sodium, Rifamastene and Otofa. It is also listed for alternate use as: API Impurity, API Intermediate. Its PubChem CID is 23702994.
Rifamycin sodium
| CAS No | 14897-39-3 |
|---|---|
| Molecular Formula | C37H46NNaO12 |
| Molecular Weight | 719.7 g/mol |
| Synonyms | sodium;(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-13-acetyloxy-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-27-olate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rifamycin sodium primary indications include the treatment of tuberculosis, leprosy, and other bacterial infections resistant to more common antibiotics. In recent years, research has also explored its potential in treating conditions including traveler's diarrhea and certain non-tuberculous mycobacterial infections.
The listed CAS number is 14897-39-3.
The listed molecular formula is C37H46NNaO12.
The listed molecular weight is 719.7 g/mol.
sodium;(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-13-acetyloxy-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-27-olate.
The source lists Rifamycin SV sodium, Rifamastene and Otofa.